Developing Complex Therapies to Tackle Complex Diseases

29/05/2024 23 min Episodio 70
Developing Complex Therapies to Tackle Complex Diseases

Listen "Developing Complex Therapies to Tackle Complex Diseases"

Episode Synopsis

SalubrisBio, rather than shy away from complexity, embraces it. The company’s lead experimental therapy is an antibody fusion protein in development for both heart failure and the rare, neurodevelopmental condition amyotrophic lateral sclerosis. We spoke to Sam Murphy, CEO of SalubrisBio, about the challenges of pursuing complex diseases with complex therapies, its pipeline, and how its China-based parent has provided it financial freedom from the vagaries of the capital markets.